Astellas Pharma Retained Earnings (Accumulated Deficit) 2012-2024 | ALPMY
Astellas Pharma retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $5.016B, a 41.3% decline year-over-year.
- Astellas Pharma retained earnings (accumulated deficit) for 2024 were $5.36B, a 21.5% decline from 2023.
- Astellas Pharma retained earnings (accumulated deficit) for 2023 were $6.828B, a 11.78% decline from 2022.
- Astellas Pharma retained earnings (accumulated deficit) for 2022 were $7.74B, a 9.87% decline from 2021.